[go: up one dir, main page]

FR16C0015I2 - Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants - Google Patents

Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants

Info

Publication number
FR16C0015I2
FR16C0015I2 FR16C0015C FR16C0015C FR16C0015I2 FR 16C0015 I2 FR16C0015 I2 FR 16C0015I2 FR 16C0015 C FR16C0015 C FR 16C0015C FR 16C0015 C FR16C0015 C FR 16C0015C FR 16C0015 I2 FR16C0015 I2 FR 16C0015I2
Authority
FR
France
Prior art keywords
pref
iii
pertussis
perposting
cellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR16C0015C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/433,646 external-priority patent/US5877298A/en
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Publication of FR16C0015I1 publication Critical patent/FR16C0015I1/fr
Application granted granted Critical
Publication of FR16C0015I2 publication Critical patent/FR16C0015I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR16C0015C 1995-05-04 2016-04-27 Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants Active FR16C0015I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/433,646 US5877298A (en) 1995-05-04 1995-05-04 Acellular pertussis vaccines and methods of preparing thereof
US50174395A 1995-07-12 1995-07-12
PCT/CA1996/000279 WO1996034883A1 (fr) 1995-05-04 1996-05-02 Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants

Publications (2)

Publication Number Publication Date
FR16C0015I1 FR16C0015I1 (fr) 2016-06-10
FR16C0015I2 true FR16C0015I2 (fr) 2017-06-09

Family

ID=27029924

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0015C Active FR16C0015I2 (fr) 1995-05-04 2016-04-27 Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants

Country Status (17)

Country Link
US (1) US6399076B2 (fr)
EP (7) EP1405643A1 (fr)
CN (2) CN100387618C (fr)
AT (3) ATE228851T1 (fr)
AU (2) AU710538B2 (fr)
BR (2) BR9608115A (fr)
CA (3) CA2220063C (fr)
DE (3) DE69622555T2 (fr)
DK (3) DK0826001T3 (fr)
ES (2) ES2182971T3 (fr)
FR (1) FR16C0015I2 (fr)
LU (1) LU93036I2 (fr)
MX (1) MX9708481A (fr)
NL (1) NL300804I2 (fr)
NZ (2) NZ306391A (fr)
PT (3) PT826001E (fr)
WO (2) WO1996034623A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) * 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
US6051240A (en) * 1994-04-28 2000-04-18 Takeda Chemical Industries, Ltd. Method of separating protective components of Bordetella pertussis
US6696065B1 (en) * 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
DK0914153T3 (da) * 1996-07-02 2007-01-29 Sanofi Pasteur Ltd Multivalente DTP-poliovacciner
AU774649B2 (en) * 1998-10-21 2004-07-01 Kitasato Daiichi Sankyo Vaccine Co.,Ltd. Vaccine preparations containing attenuated toxin
WO2005051985A2 (fr) * 2003-11-20 2005-06-09 Sanofi Pasteur, Inc. Procedes de purification de l'anatoxine coquelucheuse et peptides utiles pour ceux-ci
NZ555889A (en) * 2004-12-17 2009-07-31 Staat Der Nederlanden Vert Doo Deacylation of LPS in gram negative bacteria
PL1942932T3 (pl) * 2005-08-08 2013-11-29 Univ Oregon Health & Science Inaktywacja patogenów nadtlenkiem wodoru do wytwarzania szczepionek
EP1867638A1 (fr) * 2006-06-16 2007-12-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Procédé pour le lien de deux molécules par une réaction Diels-Alder avec une demande d'électron inverse
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
CN100537767C (zh) * 2007-04-29 2009-09-09 中国药品生物制品检定所 百日咳疫苗保护性抗原的重组表达及其应用
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
US20100330158A1 (en) * 2009-03-31 2010-12-30 Innopharma, Llc Protein-assisted drug delivery system for the targeted administration of active agents
EP2430040A1 (fr) 2009-05-11 2012-03-21 Novartis AG Procédé de purification d'antigène pour un antigène de pertactine
WO2013043608A1 (fr) * 2011-09-20 2013-03-28 Bio-Rad Laboratories, Inc. Élimination d'agents virucides de préparations biomoléculaires
WO2013049535A2 (fr) 2011-09-30 2013-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Vaccin antigrippal
CN102584958A (zh) * 2012-02-08 2012-07-18 北京天坛生物制品股份有限公司 百日咳杆菌69kd外膜蛋白的纯化方法
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
CN105007936B (zh) * 2013-03-08 2018-10-02 扬森疫苗与预防公司 无细胞百日咳疫苗
SG10201911134QA (en) 2015-06-05 2020-01-30 Grace W R & Co Adsorbent bioprocessing clarification agents and methods of making and using the same
CN105106947A (zh) * 2015-07-21 2015-12-02 华兰生物工程股份有限公司 过氧化氢脱毒的无细胞百日咳疫苗及其制备方法
EP4070815A1 (fr) 2016-10-03 2022-10-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Immunogènes de peptides de fusion env du vih-1 et leur utilisation
US11202824B2 (en) 2016-10-31 2021-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
EP3600405A1 (fr) 2017-03-24 2020-02-05 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Domaines externes modifiés masqués par le glycane du vih-1, gp120, et leur utilisation
KR102426041B1 (ko) * 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
EP3697440A1 (fr) 2017-10-16 2020-08-26 The United States of America, as represented by the Secretary, Department of Health and Human Services Protéines d'enveloppe recombinées du vih-1 et leur utilisation
US12053519B2 (en) 2018-09-23 2024-08-06 The United States Of America, As Represented By The Secretary Department Of Health And Human Services HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
WO2020086483A1 (fr) 2018-10-22 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéine gp120 de recombinaison à délétion de la boucle v1
CN110358802B (zh) * 2019-08-16 2021-06-18 长春百克生物科技股份公司 一种去除百日咳组分菌毛蛋白2/3内毒素的方法
US12210017B2 (en) 2020-01-08 2025-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptides representing epitopes from filoviruses
CN112094354B (zh) * 2020-11-05 2021-02-02 苏州世诺生物技术有限公司 副鸡禽杆菌基因工程亚单位疫苗、其制备方法及应用
AU2022323509A1 (en) 2021-08-03 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
US20250197455A1 (en) 2022-03-27 2025-06-19 TThe United States of America, as represented by the Secretary, Department of Health and Human Servi Base-covered hiv-1 envelope ectodomains and their use
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗
WO2024249626A1 (fr) 2023-05-30 2024-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Trimères en tandem triple de l'enveloppe du vih-1 et leur utilisation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
US4705686A (en) 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
WO1989001976A1 (fr) * 1987-09-04 1989-03-09 Amgen Inc. Analogues de sous-unites de toxine de bordetella derives d'adn recombinant
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
US4967176A (en) * 1988-07-15 1990-10-30 Raychem Corporation Assemblies of PTC circuit protection devices
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
EP0474646A4 (en) * 1989-03-31 1992-10-21 Washington University Bordetella vaccines
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
US6051240A (en) 1994-04-28 2000-04-18 Takeda Chemical Industries, Ltd. Method of separating protective components of Bordetella pertussis
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof

Also Published As

Publication number Publication date
CN1198099A (zh) 1998-11-04
CA2433502A1 (fr) 1996-11-07
EP0826001A1 (fr) 1998-03-04
EP1405643A1 (fr) 2004-04-07
BR9608114A (pt) 2000-10-31
CN100387618C (zh) 2008-05-14
US6399076B2 (en) 2002-06-04
CA2220048A1 (fr) 1996-11-07
ATE228851T1 (de) 2002-12-15
DE69622555D1 (de) 2002-08-29
WO1996034623A1 (fr) 1996-11-07
MX9708481A (es) 1998-02-28
AU715417B2 (en) 2000-02-03
NZ306392A (en) 1999-04-29
EP1234579A1 (fr) 2002-08-28
DE69625191T2 (de) 2003-07-10
US20010009666A1 (en) 2001-07-26
DE69638326D1 (de) 2011-03-10
EP1233022A1 (fr) 2002-08-21
AU5494196A (en) 1996-11-21
DK1393744T3 (da) 2011-05-30
EP1234580A1 (fr) 2002-08-28
EP1233022B1 (fr) 2015-12-09
EP1393744A1 (fr) 2004-03-03
CN1193324A (zh) 1998-09-16
EP0824358B1 (fr) 2002-12-04
NL300804I2 (fr) 2016-11-01
PT1393744E (pt) 2011-05-03
PT826001E (pt) 2002-12-31
BR9608115A (pt) 2004-07-13
CA2220063C (fr) 2003-08-26
EP1393744B1 (fr) 2011-01-26
CA2220048C (fr) 2006-03-07
DE69622555T2 (de) 2003-03-27
EP0824358A1 (fr) 1998-02-25
ATE496634T1 (de) 2011-02-15
ES2180758T3 (es) 2003-02-16
DK0824358T3 (da) 2003-01-27
NZ306391A (en) 1999-03-29
PT824358E (pt) 2003-02-28
DK0826001T3 (da) 2002-11-18
AU5494096A (en) 1996-11-21
WO1996034883A1 (fr) 1996-11-07
DE69625191D1 (de) 2003-01-16
LU93036I2 (fr) 2016-06-21
EP0826001B1 (fr) 2002-07-24
ATE221081T1 (de) 2002-08-15
ES2182971T3 (es) 2003-03-16
HK1016191A1 (zh) 1999-10-29
CA2220063A1 (fr) 1996-11-07
AU710538B2 (en) 1999-09-23
FR16C0015I1 (fr) 2016-06-10

Similar Documents

Publication Publication Date Title
FR16C0015I2 (fr) Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants
AU4267093A (en) Vaccine compositions for mucosal delivery
RU99101850A (ru) Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно(акдс)-полиомиелитные вакцины
EP0761230A3 (fr) Vaccin contenant la protéine de la membrane externe de Bordetella pertusis et procédé de préparation
AU710475B2 (en) Acellular pertussis vaccine with diphtheria- and tetanus-toxoids
LU91155I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutininine filamenteuse, de pertactine, d'agglutinogènes fimbriaux coquelucheux 2 et 3 et de virus poliomyélitique inactivé type 1, type 2 et type 3.
CA2386023A1 (fr) Vaccins dtpa des muqueuses vaccines
WO1997046255A3 (fr) Composition vaccinale comprenant des fragments proteiniques de la membrane exterieure du bordetella pertussis
US8623380B2 (en) Acellular pertussis vaccine with diphthriae- and tetanus-toxoids
MXPA99004278A (es) Vacuna de pertusis acelular con toxoides de difteria y tetanos